AbbVie Agrees to Terms to Acquire Aliada Therapeutics

Posted on by admin

Acquisition includes Aliada’s lead asset, ALIA-1758, which is being developed for the treatment of Alzheimer disease.

Leave a Reply

Your email address will not be published. Required fields are marked *